187 related articles for article (PubMed ID: 34327344)
1. Effectiveness and safety of iguratimod treatment in patients with active rheumatoid arthritis in Chinese: A nationwide, prospective real-world study.
Mu R; Li C; Li X; Ke Y; Zhao L; Chen L; Wu R; Wu Z; Zuo X; Xie Y; Chen J; Wei W; Liu Y; Li Z; Dai L; Sun L; Liu X; Li Z
Lancet Reg Health West Pac; 2021 May; 10():100128. PubMed ID: 34327344
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and Safety of Iguratimod Monotherapy or Combined With Methotrexate in Treating Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
Ouyang D; Ma YZ; Zou J; Wang YL; Chen Z; Yang YY; Zou B; Li X; Cao JZ
Front Pharmacol; 2022; 13():911810. PubMed ID: 35991879
[No Abstract] [Full Text] [Related]
3. The Effect and Safety of Iguratimod Combined With Methotrexate on Rheumatoid Arthritis: A Systematic Review and Meta-Analysis Based on a Randomized Controlled Trial.
Zeng L; Yu G; Yang K; Hao W; Chen H
Front Pharmacol; 2021; 12():780154. PubMed ID: 35115930
[No Abstract] [Full Text] [Related]
4. Effectiveness of iguratimod as monotherapy or combined therapy in patients with rheumatoid arthritis: a systematic review and meta-analysis of RCTs.
Hu CJ; Zhang L; Zhou S; Jiang N; Zhao JL; Wang Q; Tian XP; Zeng XF
J Orthop Surg Res; 2021 Jul; 16(1):457. PubMed ID: 34271950
[TBL] [Abstract][Full Text] [Related]
5. Non-invasive vagus nerve stimulation for rheumatoid arthritis: a proof-of-concept study.
Marsal S; Corominas H; de Agustín JJ; Pérez-García C; López-Lasanta M; Borrell H; Reina D; Sanmartí R; Narváez J; Franco-Jarava C; Peterfy C; Narváez JA; Sharma V; Alataris K; Genovese MC; Baker MC
Lancet Rheumatol; 2021 Apr; 3(4):e262-e269. PubMed ID: 38279410
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study).
Kennedy WP; Simon JA; Offutt C; Horn P; Herman A; Townsend MJ; Tang MT; Grogan JL; Hsieh F; Davis JC
Arthritis Res Ther; 2014 Oct; 16(5):467. PubMed ID: 25359150
[TBL] [Abstract][Full Text] [Related]
7. The Effectiveness and Retention Rate of Iguratimod in Japanese Rheumatoid Arthritis Patients with/without Methotrexate in Daily Medical Care.
Inoue A; Nozaki Y; Hirooka Y; Kinoshita K; Chiba Y; Funauchi M; Matsumura I
Life (Basel); 2020 Oct; 10(11):. PubMed ID: 33138014
[TBL] [Abstract][Full Text] [Related]
8. [The efficacy and safety of tocilizumab combined with disease-modifying anti-rheumatoid drugs in the treatment of active rheumatoid arthritis: a multi-center, randomized, double-blinded, placebo-controlled trial].
Shi Q; Zhao Y; Bao CD; Li XF; Huang F; Zhu P; Li ZG; Gu JR; Zhang ZY; Zhao DB; Zhao SL; Jiang QD; Tian J; Zhang FC
Zhonghua Nei Ke Za Zhi; 2013 Apr; 52(4):323-9. PubMed ID: 23925361
[TBL] [Abstract][Full Text] [Related]
9. [Adalimumab plus methotrexate for the treatment of rheumatoid arthritis: a multi-center randomized, double-blind, placebo-controlled clinical study.].
Huang F; Zhang FC; Bao CD; Tao Y; Gu JR; Xu JH; Zhu P; Xu HJ; Zhang ZY; Zhao DB; Wu DH
Zhonghua Nei Ke Za Zhi; 2009 Nov; 48(11):916-21. PubMed ID: 20079321
[TBL] [Abstract][Full Text] [Related]
10. Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens.
Zintzaras E; Dahabreh IJ; Giannouli S; Voulgarelis M; Moutsopoulos HM
Clin Ther; 2008 Nov; 30(11):1939-55. PubMed ID: 19108784
[TBL] [Abstract][Full Text] [Related]
11. Safety and effectiveness of 24-week treatment with iguratimod, a new oral disease-modifying antirheumatic drug, for patients with rheumatoid arthritis: interim analysis of a post-marketing surveillance study of 2679 patients in Japan.
Mimori T; Harigai M; Atsumi T; Fujii T; Kuwana M; Matsuno H; Momohara S; Takei S; Tamura N; Takasaki Y; Ikeuchi S; Kushimoto S; Koike T
Mod Rheumatol; 2017 Sep; 27(5):755-765. PubMed ID: 27919207
[TBL] [Abstract][Full Text] [Related]
12. Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of etanercept in patients with moderately active rheumatoid arthritis despite DMARD therapy.
Hobbs K; Deodhar A; Wang B; Bitman B; Nussbaum J; Chung J; Collier DH
Springerplus; 2015; 4():113. PubMed ID: 25793152
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3).
Tanaka Y; Takeuchi T; Tanaka S; Kawakami A; Iwasaki M; Song YW; Chen YH; Wei JC; Lee SH; Rokuda M; Izutsu H; Ushijima S; Kaneko Y; Akazawa R; Shiomi T; Yamada E
Ann Rheum Dis; 2019 Oct; 78(10):1320-1332. PubMed ID: 31350270
[TBL] [Abstract][Full Text] [Related]
14. Clinical effectiveness of iguratimod based on real-world data of patients with rheumatoid arthritis.
Mizutani S; Kodera H; Sato Y; Nanki T; Yoshida S; Yasuoka H
Clin Rheumatol; 2021 Jan; 40(1):123-132. PubMed ID: 32506311
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of iguratimod in the treatment of rheumatic and autoimmune diseases: a meta-analysis and systematic review of 84 randomized controlled trials.
Zeng L; He Q; Deng Y; Li Y; Chen J; Yang K; Luo Y; Ge A; Zhu X; Long Z; Sun L
Front Pharmacol; 2023; 14():1189142. PubMed ID: 38143490
[No Abstract] [Full Text] [Related]
16. Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews.
Scott DL; Ibrahim F; Farewell V; O'Keeffe AG; Ma M; Walker D; Heslin M; Patel A; Kingsley G
Health Technol Assess; 2014 Oct; 18(66):i-xxiv, 1-164. PubMed ID: 25351370
[TBL] [Abstract][Full Text] [Related]
17. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of 99Tc-methylene diphosphonate as a disease-modifying anti-rheumatic drug (DMARD) in combination with conventional synthetic (cs) DMARDs in the treatment of rheumatoid arthritis: A systematic review and meta-analysis of 34 randomized controlled trials.
Deng G; Chen X; Shao L; Wu Q; Wang S
Heliyon; 2023 Nov; 9(11):e21691. PubMed ID: 37942155
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy.
Li Z; Zhang F; Kay J; Fei K; Han C; Zhuang Y; Wu Z; Hsia EC
Int J Rheum Dis; 2016 Nov; 19(11):1143-1156. PubMed ID: 26259617
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
Genovese MC; Fleischmann R; Combe B; Hall S; Rubbert-Roth A; Zhang Y; Zhou Y; Mohamed MF; Meerwein S; Pangan AL
Lancet; 2018 Jun; 391(10139):2513-2524. PubMed ID: 29908670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
